An investigation on behalf of investors in Intrexon Corp (NYSE:XON) shares over potential wrongdoing at Intrexon Corp was announced and NYSE:XON stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 09/08/2016 -- An investigation on behalf of investors in shares of Intrexon Corp (NYSE:XON) was announced over potential breaches of fiduciary duties by certain directors at Intrexon.
Investors who purchased shares of Intrexon Corp (NYSE:XON) and currently hold any of those NYSE:XON shares have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Intrexon directors breached their fiduciary duties and caused damage to the company and its shareholders.
On April 21, 2016, a report was published on Intrexon Corp asserting, among other things, that Intrexon's technology has recently been questioned by high-ranking officials from the WHO, CDC and NIH, that Intrexon overstated revenues by 50% through transactions with related parties, thatIntrexon's technology platform is an overhyped, undifferentiated collection of commodity and failed products, and that Intrexon is the Theranos of the public markets.
On May 3, 2016 a lawsuit was filed against Intrexon Corp (NYSE:XON) over alleged securities laws violations. The plaintiff claimd that between May 12, 2015 and April 20, 2016 the defendants issued false and misleading financial statements to investors.
Those who purchased shares of Intrexon Corp have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego